| Prev Close | 148.75 |
| Day Low/High | 146.01 / 148.34 |
| 52 Wk Low/High | 109.16 / 157.00 |
| Avg Volume | 11.53M |
Johnson & Johnson (JNJ)
147.60
1.20
0.77
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.63B |
| Market Cap | 391.90B |
| EPS | 5.70 |
| P/E Ratio | 23.21 |
| Div & Yield | 4.04 (2.59%) |
Jim Cramer on Johnson & Johnson's Pharmaceuticals Sales Growth
When investors review a drug company, pay close attention to its pharma performance, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.
Jim Cramer on Netflix, Goldman Sachs, Bank of America and Johnson & Johnson
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Tuesday's trending stocks from the floor of the New York Stock Exchange.
Highs (and Lows) of FANG Trading: Market Recon
My Netflix short was a big winner yesterday, but I am also long Amazon and Google, which were hit with pretty strong collateral damage.
Bank Leadership Is Covering Up Some Ugly Market Issues
This quarter Netflix is not going to be the star of earnings season.
Closing Bell: LIVE MARKETS BLOG
The major U.S. indices rose on Friday, closing out the week on a two-day winning streak.
Jim Cramer: This Market Isn't Done Going Higher
We aren't done moving higher even with the president ready to strike at a moment's notice against any of our allies.
Stocks Rise Modestly and 4 Other Stories to Watch Premarket Friday
Happy Friday the 13th! These are the stories moving the market ahead of today's opening bell.
REPLAY: Jim Cramer on Broadcom, CA, Johnson & Johnson, Citigroup & Canopy Growth
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Thursday's trending stocks from the floor of the New York Stock Exchange
Jim Cramer: This Market Is Not as Expensive as It Looks
The only way the market is "dangerously elevated" is if you believe that 2019 is going to be a horrendous year.
Crowning Achievement: Six Dividend Kings With 50+ Years of Rising Dividends
These 'recession-resistant' names have proven they can thrive in a variety of economic conditions and through changing technologies and sentiments.
The Charts and Indicators on Johnson & Johnson Are Still Mostly Bearish
Johnson & Johnson is among the companies that Jim Cramer has put on his new GLOOM index.
Jim Cramer: A GLUM Index For Gloomy Markets
Taking the measure of what's keeping the markets in the dumps.
Tesla, Boeing and Merck Among Companies Hurt by Latest Tariffs
The latest announcement from the U.S. Trade Representative's office is chilling reading for free trade supporters.
Latest Reasons to Avoid Alzheimer's Plays
Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.
Jim Cramer: Tech Can't Do it All Alone
Tech and retail gains aren't enough to lead markets to new highs.
Intermediate Trade: Johnson & Johnson
JNJ is one of the best of breed of the pharmaceuticals sector.
Knowledge Is Power in Buy & Sell Decisions
Johnson & Johnson is a premiere company, but the trick is knowing when to buy it.
How to Play the Long Side of Johnson & Johnson
Shares of the healthcare giant pick up a quant rating upgrade as the charts suggest gains ahead.
2 Trading Opportunities in Health Care
The potential of these setups on the weekly chart is rather good.
Checked the 52-Week Low List Lately? It's a Graveyard of Well-Known Stocks
What's really surprising is the emergence of so many household names on the list.
Jim Cramer: Reports of FANG's Death Greatly Exaggerated
The big story is about cloud adoption.
Where (and How) to Find 'Dividend Aristocrats'
The Nasdaq U.S. Broad Dividend Achievers Index is a good place to start.
Jim Cramer: Markets Seek Domestic Tranquility
Stock markets ran higher as investors turned towards domestic-focused companies.
60 Seconds: Own Dividend Stocks And Get Paid While The Market Tanks (Video)
It's hard to watch the market fall. But knowing you're still getting paid while it happens can make it much more palpable. That's why you need to have some dividend-producing stocks in your portfolio. Watch our video to find out why!
Closing Bell: LIVE MARKETS BLOG
Markets were able to close the day in the green after a volatile day of trading.
Jim Cramer: Will the Techs Be Challenged, Too?
The theft of intellectual property can be confronted by a Section 301 challenge directly from the trade representative.
An Updated Technical Strategy on Johnson & Johnson
Let's check and see how things are going.
Cramer: The Right Stocks Rallied Today
Merger news, healthcare gains, industrials and even airlines joined the party.
Johnson & Johnson Poised to Move Higher, Buy Available Weakness
With JNJ now set to close above $134, another look is in order.
Jim Cramer: You Have to Decide If You Want to Profit From This Moment
We have a different kind of market where you must know the SYMBOLS and know what the companies do that are the symbols.
